> ## Content Index
> Fetch the complete content index at: https://chinapharmadesk.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# China's dual commercial drug lists split hospital DRG exemptions from retail oncology rebates
- URL: https://chinapharmadesk.com/china-dual-commercial-drug-lists-nhsa-iac/
- Published: 2026-11-19T14:55:51.000Z
- Updated: 2026-11-19T14:55:54.000Z
- Description: China's NHSA 28-drug Commercial Innovative List (Notice No. 29) and IAC's 58-item insurance recommendation list share only 10 oncology products, splitting Huiminbao DRG exemptions from retail rebates.
- Author: Lin Yi
- Tags: Desk analysis, Market Access, Oncology & ADC, Hengrui Pharma

With the [Insurance Association of China (IAC) publishing its 58-item *Commercial Health Insurance Recommended Drug and Device List (First Edition)*](https://www.iachina.cn/attach/0/30472dde061d4cf083154fd0c5c4382d.pdf?ref=chinapharmadesk.com) alongside three sets of model medical insurance clauses ([IAC Q&A, November 10, 2026](https://www.iachina.cn/art/2026/11/10/art%5F22%5F109384.html?ref=chinapharmadesk.com)) and the [National Healthcare Security Administration (NHSA) issuing its 28-drug *Commercial Health Insurance Innovative Drug List (2026)*](https://www.nhsa.gov.cn/art/2026/11/14/art%5F104%5F23384.html?ref=chinapharmadesk.com) under Notice No. 29 on November 14, multinational and domestic drugmakers now face two parallel commercial insurance formularies in China that share only **10 oncology products**. Rather than converging into a single “Category C” private payer tier, the two lists split China’s supplementary health insurance market by product architecture, hospital regulatory privileges, and pricing mechanics: the NHSA’s 28-drug catalogue pairs confidential front-end price negotiation with public-hospital Diagnosis-Related Group (`DRG`) and drug-spending cap exemptions primarily for city-customized `Huiminbao` plans, whereas the IAC’s 58-item list—voted on by 54 health insurers—targets out-of-hospital specialty pharmacy riders in individual Million-RMB Medical Insurance (`Baiwan Yiliaoxian`) without upfront list-price cuts, relying instead on post-facto volume rebates of roughly 3% to 15% while enjoying no public-hospital assessment waivers.

As examined in our [2026 NRDL and Commercial List overhaul analysis](https://chinapharmadesk.com/china-2026-nrdl-commercial-list-bridge/) and [four-ministry hospital formulary policy review](https://chinapharmadesk.com/china-class1-hospital-formulary-policy/), overseas market-access teams frequently treat “commercial health insurance inclusion” in China as a unified regulatory milestone. A side-by-side audit of the full 58-item IAC PDF (`30472dde061d4cf083154fd0c5c4382d.pdf`) and the 28-drug NHSA 2026 Commercial Innovative Drug List PDF reveals why portfolio strategy, hospital prescription routing, and gross-to-net contracting diverge sharply between the two tracks.

## Two formularies, two payer vehicles, and only 10 overlapping oncology therapies

The structural split begins with who compiled each list and which insurance contracts must reference it:

| Dimension                                | NHSA *Commercial Health Insurance Innovative Drug List (2026)*                                                                                                                                                                              | IAC *Commercial Health Insurance Recommended Drug & Device List (1st Ed.)*                                                                                                                                                                                        |
| ---------------------------------------- | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |
| **Issuing authority & date**             | National Healthcare Security Administration (NHSA) & Ministry of Human Resources and Social Security (MOHRSS), Notice No. 29 (Nov 14, 2026; effective Jan 1, 2027)                                                                          | Insurance Association of China (IAC) Health Insurance Specialty Committee & China Association of Actuaries (CAA) (Nov 10, 2026)                                                                                                                                   |
| **Total covered items**                  | **28 prescription drugs** (19 inaugural 2025 drugs minus 2 transitioned to 2026 basic NRDL \+ 12 new 2026 additions; see note on net 28-drug table)                                                                                         | **58 drugs and medical devices** (57 oncology drugs + 1 device, Tumor Treating Fields / Optune, Guoxie Zhujin 20203090269)                                                                                                                                        |
| **Selection & voting mechanism**         | Manufacturer application + NHSA pharmacoeconomic and actuarial assessment + bilateral price/payment negotiation                                                                                                                             | Actuarial dossier prep by CAA; clinical scoring by 22 randomly drawn medical experts (from a 90+ expert pool); commercial voting by **54 health insurers** across 5 criteria (market demand, claims experience, drug/company reputation, partnership willingness) |
| **Primary insurance vehicle**            | Municipal government-guided inclusive plans (Huiminbao), corporate group supplementary plans, and multi-tier mutual aid                                                                                                                     | Individual short-term (51-clause) and long-term (59-clause) general commercial medical insurance (Baiwan Yiliaoxian and mid-tier medical plans) adopting IAC model clauses                                                                                        |
| **Coverage setting**                     | Public-hospital inpatient/outpatient and designated [Dual-Channel (Shuangtongdao)](https://chinapharmadesk.com/china-pharma-glossary/) pharmacies                                                                                           | **Strictly out-of-hospital (Yuanwai Teding Yaoxie Zeren)**: covers external specialty pharmacy purchases (inpatient hospital drugs are already covered by standard medical policies without a drug list)                                                          |
| **Basic NRDL overlap**                   | **0%** — mutually exclusive with basic NRDL; NHSA and basic injury/medical funds are barred from paying                                                                                                                                     | **\~45% (26 of 58) are already in the basic NRDL**; **32 items (\~55%)** are self-pay outside the basic NRDL (plus relma-cel, which transitions into the basic NRDL on Jan 1, 2027)                                                                               |
| **Therapeutic scope & product maturity** | Frontier oncology (CAR-T, bispecifics, 177Lu radioligand) **plus** rare metabolic, hematologic, and neurodegenerative therapies (Alzheimer's, ATTRv-PN, SOD1-ALS, hemophilia B gene therapy, XLH, aTTP); average time on market \~27 months | **100% oncology and hematologic malignancies** (solid tumors, lymphomas, leukemias, myeloma, neuroblastoma, giant cell tumor of bone); 25 Class 1 + 2 Class 2 new drugs; average time on market \~67 months                                                       |
| **Pricing & gross-to-net model**         | **Front-end negotiated ceiling / confidential discount** (15%–50%+ off list price) locked before inclusion                                                                                                                                  | **No upfront list-price cut** (100% of provincial guawang listing price preserved); insurers negotiate post-facto volume rebates (3%–15%) with manufacturers                                                                                                      |
| **Hospital DRG/DIP & cap exemptions**    | **Yes** — explicitly exempted by NHSA Notice No. 29 and four-ministry Notice No. 18 from hospital self-pay ratio caps, DRG/DIP case-weight penalties, and VBP substitution monitoring                                                       | **No** — excluded from the four-ministry hospital assessment waiver; prescriptions rely on physicians directing patients to out-of-hospital specialty pharmacies                                                                                                  |

Cross-matching the 28 drugs on the NHSA 2026 Commercial Innovative Drug List against the 58 items on the IAC Recommended List shows that **only 10 products appear on both lists**:

1. **Five autologous hematologic `CAR-T` therapies**: Fosun Kite’s axicabtagene ciloleucel (`axi-cel` / `Yescarta`, `Guoyao Zhunzi S20210019`), Juventas Cell Therapy’s inaticabtagene autoleucel (`Yuanruida`, `S20230065` / `S20250063`), IASO Bio’s equecabtagene autoleucel (`Fucaso`, `S20230040`), CARsgen’s (`HKEX: 02171`) zevorcabtagene autoleucel (`Saikaize`, `S20240006`), and Chongqing Precision Biotech’s prucacabtagene autoleucel (`Pulidekai`, `S20250058` / `S20250059`). *(Note:* [*JW Therapeutics’ (HKEX: 02126) relma-cel (Carteyva, S20210035)*](https://chinapharmadesk.com/jw-relma-cel-288600-nrdl-cost-math/) *is Item #30 on the IAC list, having graduated from the 2025 NHSA Commercial List into the 2026 basic `NRDL` at RMB 288,600).*
2. **Two anti-GD2 neuroblastoma antibodies**: Recordati and BeOne Medicines’ (`HKEX: 06160`; `SSE: 688235`; `NASDAQ: ONC`) dinutuximab beta (`Qarziba`, `SJ20210023`) and Y-mAbs / SciClone’s naxitamab (`Danyelza`, `SJ20220019`).
3. **Three solid-tumor and immuno-oncology assets**: BeOne and Jazz Pharmaceuticals’ (`NASDAQ: JAZZ`) HER2 bispecific zanidatamab (`Ziihera` / `Baihe'an`, `S20250030`), Bristol Myers Squibb’s (`NYSE: BMY`) anti-CTLA-4 ipilimumab (`Yervoy`, `SJ20210019` / `SJ20210020`), and Sirtex / Grand Pharma’s (`HKEX: 00512`) Yttrium-90 (`90Y`) resin microspheres (`SIR-Spheres` / `Yigantai`, `HJ20220004`).

## Eighteen NHSA frontier drugs—including all rare-disease and Alzheimer’s therapies—sit outside the IAC list

Equally revealing is what the 54 commercial insurers left off the IAC’s 58-item baseline list. **Eighteen of the 28 drugs** on the NHSA’s 2026 Commercial Innovative Drug List are absent from the IAC recommendation:

- **All 10 non-oncology rare-disease, neurodegenerative, and metabolic therapies on the NHSA list**: Eisai’s (`TSE: 4523`) lecanemab (`Leqembi` / `Leyibao`) and Eli Lilly’s (`NYSE: LLY`) donanemab (`Kisunla` / `Jinengda`) for early Alzheimer’s disease; AstraZeneca’s (`LSE/NASDAQ: AZN`) eplontersen (`Wainua` / `Wannowei`) for `ATTRv-PN`; Biogen’s (`NASDAQ: BIIB`) tofersen (`Qalsody` / `Kaishengdi`) for `SOD1-ALS`; Belief BioMed’s (`Shanghai Xinzhi`) AAV gene therapy dalnacogene ponparvovec (`Xinjiuning` / `BBM-H901`) for hemophilia B; Sanofi’s (`EPA/NASDAQ: SNY`) caplacizumab (`Cablivi`) for `aTTP`; Kyowa Kirin’s (`TSE: 4151`) burosumab (`Crysvita` / `Linping`) for `XLH` and `TIO`; CANbridge’s (`HKEX: 01228`) velaglucerase beta (`Goruining`) for Gaucher disease; Takeda’s (`TSE: 4502`) teduglutide (`Revestive`) for short bowel syndrome; and Yifan Pharmaceutical’s (`SZSE: 002019`) diazoxide oral suspension for congenital hyperinsulinism.
- **Eight high-ticket oncology therapies on the NHSA list**: CARsgen’s newly approved solid-tumor `Claudin18.2` CAR-T satricabtagene autoleucel (`satri-cel` / `Kailimei`) and Shanghai Hengrundasheng’s anti-CD19 CAR-T ranicabtagene autoleucel (`Hengkailai`); Novartis’s (`SIX: NOVN`) PSMA radioligand `177Lu-vipivotide tetraxetan` (`Pluvicto` / `Paiweituo`); Pfizer’s (`NYSE: PFE`) BCMA×CD3 bispecific elranatamab (`Elrexfio` / `Yirui'ou`); Johnson & Johnson’s (`NYSE: JNJ`) GPRC5D×CD3 bispecific talquetamab (`Talvey` / `Tuolike`); Kyowa Kirin’s mogamulizumab (`Poteligeo`); PharmaMar / Luye Pharma’s (`HKEX: 02186`) lurbinectedin (`Zepzelca`); and RedSun’s para-toluenesulfonamide injection (`Puluoxian'an`).

Why did commercial insurers exclude all 10 non-oncology NHSA commercial-list drugs from their core `Baiwan Yiliaoxian` outpatient drug schedule? Under the IAC’s November 10 model clauses, standard short-term and long-term commercial medical policies cover general inpatient hospitalization expenses plus an **out-of-hospital malignant-tumor specialty drug rider (`Yuanwai Teding Yaoxie Zeren`)**. Because individual `Baiwan Yiliaoxian` policies are underwritten around acute catastrophic hospitalization and outpatient cancer therapy—and explicitly exclude pre-existing chronic genetic or neurodegenerative conditions—insurers voted almost exclusively for established oncology blockbusters with predictable outpatient claim curves.

## Roche and BeOne dominate the IAC 58-item list, while Novartis and J&J score zero

Because the IAC’s 58-item list is mandatory for any individual short-term or long-term commercial medical policy that adopts the association’s 2026 model clauses, inclusion secures baseline formulary placement across China’s RMB 28 billion+ `Baiwan Yiliaoxian` market without requiring individual third-party administrator (`TPA`) negotiations product by product.

Auditing all 58 approval numbers on the IAC list shows a stark concentration among companies that combined broad basic-`NRDL` oncology franchises with high-demand self-pay ADCs and checkpoint inhibitors:

| Company (Ticker)                                                                               | Total IAC List Items (of 58) | Basic NRDL Anchor Products on IAC List                                                                                                                                                                    | Self-Pay / Commercial-List Products on IAC List                                               |
| ---------------------------------------------------------------------------------------------- | ---------------------------- | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | --------------------------------------------------------------------------------------------- |
| **Roche** (SIX: ROG)                                                                           | **11**                       | Alecensa (alectinib), Avastin (bevacizumab), Gazyva (obinutuzumab), Herceptin (trastuzumab), MabThera (rituximab), Perjeta (pertuzumab), Phesgo (pertuzumab/trastuzumab SC), Polivy (polatuzumab vedotin) | Tecentriq (atezolizumab), Columvi (glofitamab), Itovebi (inavolisib, approved 2025)           |
| **BeOne Medicines** (HKEX: 06160; SSE: 688235; NASDAQ: ONC) *(incl. licensed China portfolio)* | **7**                        | Brukinsa (zanubrutinib), Tevimbra (tislelizumab), Baiyueda (sonrotoclax, entered 2026 NRDL), Xgeva (denosumab), Blincyto (blinatumomab)                                                                   | Ziihera (zanidatamab, also on NHSA 28 list), Qarziba (dinutuximab beta, also on NHSA 28 list) |
| **AstraZeneca** (LSE/NASDAQ: AZN) *(incl. Daiichi Sankyo co-promoted Enhertu)*                 | **5**                        | Tagrisso (osimertinib), Lynparza (olaparib), Enhertu (trastuzumab deruxtecan)                                                                                                                             | Imfinzi (durvalumab), Imjudo (tremelimumab, SJ20260025/26)                                    |
| **Jiangsu Hengrui** (SSE: 600276; HKEX: 01276)                                                 | **3**                        | Aiwida (trastuzumab rezetecan, SHR-A1811)                                                                                                                                                                 | Airuili (adebrelimab), Aizeli (retlirafusp alfa, SHR-1701, S20260002)                         |
| **Astellas Pharma** (TSE: 4503) *(incl. Pfizer/Seagen partner asset)*                          | **3**                        | Xospata (gilteritinib)                                                                                                                                                                                    | Padcev (enfortumab vedotin), Vyloy (zolbetuximab, SJ20240050)                                 |
| **Zai Lab** (NASDAQ: ZLAB; HKEX: 09688)                                                        | **3**                        | Zejula (niraparib)                                                                                                                                                                                        | Optune (TTFields), Tivdak (tisotumab vedotin, SJ20260036)                                     |
| **Akeso** (HKEX: 09926)                                                                        | **2**                        | Kaitanni (cadonilimab), Idafang (ivonescimab)                                                                                                                                                             | *(Early-line / self-pay indications outside NRDL scope)*                                      |
| **Ascentage Pharma** (HKEX: 06855; NASDAQ: AAPG)                                               | **2**                        | Nailike (olverembatinib), Lishengtuo (lisaftoclax, H20250045-47, entered 2026 NRDL)                                                                                                                       | —                                                                                             |
| **Betta Pharmaceuticals** (SZSE: 300558)                                                       | **2**                        | Conmana (icotinib), Bemena (ensartinib)                                                                                                                                                                   | —                                                                                             |
| **Bristol Myers Squibb** (NYSE: BMY)                                                           | **2**                        | —                                                                                                                                                                                                         | Opdivo (nivolumab), Yervoy (ipilimumab, also on NHSA 28 list)                                 |
| **MSD** (NYSE: MRK), **Gilead** (NASDAQ: GILD), **Pfizer** (NYSE: PFE, solo)                   | **1 each**                   | Besponsa (inotuzumab ozogamicin, Pfizer)                                                                                                                                                                  | Keytruda (pembrolizumab, MSD), Trodelvy (sacituzumab govitecan, Gilead)                       |
| **Novartis** (SIX: NOVN), **Johnson & Johnson** (NYSE: JNJ)                                    | **0**                        | —                                                                                                                                                                                                         | *(Put Pluvicto and Talvey on NHSA 28 list instead; 0 items on IAC 58)*                        |

Why are 26 basic-`NRDL` drugs—such as `Tagrisso`, `Alecensa`, `Brukinsa`, `Tevimbra`, `Kaitanni`, and `Idafang`—on an out-of-hospital commercial insurance list at all? Under public-hospital `DRG/DIP` case-rate pressure and “one-drug, two-spec” (`Yipin Lianggui`) formulary caps, tertiary hospital surgeons and oncologists frequently direct patients to buy maintenance or combination therapies at retail `DTP` (`Direct-to-Patient`) pharmacies even when the molecule is nominally in the basic `NRDL`, or when a patient uses an approved indication not yet covered by the `NRDL` payment restriction. Having those drugs explicitly listed in the IAC’s 58-item out-of-hospital schedule obligates `Baiwan Yiliaoxian` policies using the model clauses to reimburse the external pharmacy receipt.

According to domestic industry disclosures reported on November 19, several multinational drugmakers underestimated the IAC selection process—either missing early actuarial data calls from the China Association of Actuaries or hesitating to commit to the **3% to 15% volume-based rebates** that commercial insurers demand behind the scenes when list prices remain untouched.

## The prescription-outflow bottleneck: DRG waivers versus retail rebate math

For market-access executives deciding where to allocate commercial resources in 2027, the operational trade-off between the two lists comes down to **hospital prescription outflow (`Chufang Wailiu`) versus net price integrity**:

- **The NHSA 28-drug list solves the hospital compliance barrier but caps the price**: Under NHSA Notice No. 29 and the [October 30 four-ministry Notice No. 18](https://chinapharmadesk.com/china-class1-hospital-formulary-policy/), drugs on the NHSA Commercial Innovative Drug List are exempted from public-hospital basic-insurance self-pay rate limits (`Jiben Yibao Zifeilv Zhibiao`), `DRG/DIP` payment caps, and `VBP` substitution monitoring. That gives public-hospital physicians regulatory cover to prescribe an ultra-high-cost drug without triggering departmental financial penalties. Yet according to first-year performance data cited by industry platform `InsRx.ai` on November 19, the inaugural 19-drug 2025 NHSA Commercial List achieved an average adoption rate of **less than 30%** across local municipal `Huiminbao` plans and generated roughly **RMB 600 million (approx. $83.0 million)** in cumulative sales across nearly 30,000 patient claims—serving primarily as a one-year data-generation bridge for products like `relma-cel` and BeOne’s `zanidatamab` before basic-`NRDL` entry.
- **The IAC 58-item list preserves provincial `guawang` list prices for global reference pricing, but lacks hospital policy protection**: Because the IAC is an insurance-industry trade body under the National Financial Regulatory Administration (`NFRA`) rather than a healthcare regulator, its 58-item list enjoys **none** of the four-ministry hospital `DRG` or self-pay rate exemptions. Moving volume through the IAC list requires a manufacturer’s field force and `DTP` pharmacy network to capture prescriptions that leak out of public hospitals, while rebating 3% to 15% of realized pharmacy volume back to participating insurers. Across China’s entire commercial health insurance market, direct specialty-drug reimbursement currently totals roughly **RMB 5 billion to RMB 12.4 billion (approx. $690 million to $1.71 billion) per year**—a fraction of total health insurance premium volume, which remains dominated by lump-sum critical illness policies (`Zhongjixian`).

The next records that will test how these two lists operate in practice arrive between December 2026 and Q1 2027: whether major commercial health insurers (`Ping An Health`, `PICC Health`, `China Life`, and `CPIC`) adopt the IAC’s November 10 model clauses verbatim in their 2027 `Baiwan Yiliaoxian` renewals and expand beyond the 58-item baseline using the China Association of Actuaries’ broader cost-modeled drug pool; how many municipal 2027 `Huiminbao` plans incorporate the 12 newly added drugs from the NHSA’s 28-drug Commercial Innovative List after January 1, 2027; and whether public hospitals implement separate electronic prescription routing for the 10 oncology drugs that sit on both formularies simultaneously.